Heart failure & cardiomyopathies
Baseline NT-proBNP nonresponse score and health status measures in assessing treatment responses in heart failure with reduced ejection fraction
Authors' conclusion
NT-proBNP nonresponse score and KCCQ-OSS was associated with persistently elevated NT-proBNP 12 months independently of baseline NT-proBNP levels.
Study context
- Population
- Patients with heart failure with reduced ejection fraction
- Participants
- 877 patients
- Comparison
- NNRS vs standard health status measures (Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), Duke Activity Status Index (DASI), 6-minute walk distance) in predicting NT-proBNP >1,000 pg/mL at 12 months
- Outcome
- NT-proBNP >1,000 pg/mL
- Follow-up
- 12 months
Methodological detailssecondary analysis of GUIDE-IT trial data, multivariable logistic regression
- Secondary analysis of GUIDE-IT trial data
- Multivariable logistic regression
Performance
As reported in the abstract
Patients with NT-proBNP >1,000 pg/mL
252
28.7%
Further findings
Discriminative capacity of NNRS for NT-proBNP >1,000 pg/mL · 12 months
- Discriminative capacity of NNRS
- 0.72 (95% CI, 0.67-0.77)
Predictors of NT-proBNP nonresponse after adjustment · 12 months
- NNRS
- P = 0.044
- KCCQ-OSS
- P = 0.002
- After adjusting for covariates, only NNRS and KCCQ-OSS remained predictive
Original publication
Baseline NT-proBNP nonresponse score and health status measures in assessing treatment responses in heart failure with reduced ejection fraction. Am Heart J. Published 25 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →